Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

Pfiz­er an­nounced Fri­day morn­ing that the FDA ap­proved its gene ther­a­py for the rare ge­net­ic bleed­ing dis­or­der he­mo­phil­ia B.

The one …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.